BeiGene Ltd. (49B) - Net Assets
Based on the latest financial reports, BeiGene Ltd. (49B) has net assets worth €3.50 Billion EUR (≈ $4.09 Billion USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.84 Billion ≈ $6.83 Billion USD) and total liabilities (€2.34 Billion ≈ $2.74 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BeiGene Ltd. (49B) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.50 Billion |
| % of Total Assets | 59.91% |
| Annual Growth Rate | 32.4% |
| 5-Year Change | -13.88% |
| 10-Year Change | N/A |
| Growth Volatility | 109.15 |
BeiGene Ltd. - Net Assets Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore 49B current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for BeiGene Ltd. (2016–2024)
The table below shows the annual net assets of BeiGene Ltd. from 2016 to 2024. For live valuation and market cap data, see 49B company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.33 Billion ≈ $3.90 Billion |
-5.80% |
| 2023-12-31 | €3.54 Billion ≈ $4.14 Billion |
-19.30% |
| 2022-12-31 | €4.38 Billion ≈ $5.12 Billion |
-29.79% |
| 2021-12-31 | €6.24 Billion ≈ $7.30 Billion |
+61.35% |
| 2020-12-31 | €3.87 Billion ≈ $4.52 Billion |
+295.48% |
| 2019-12-31 | €978.36 Million ≈ $1.14 Billion |
-44.21% |
| 2018-12-31 | €1.75 Billion ≈ $2.05 Billion |
+156.29% |
| 2017-12-31 | €684.23 Million ≈ $799.94 Million |
+93.88% |
| 2016-12-31 | €352.91 Million ≈ $412.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BeiGene Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 836942400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €11.94 Billion | 358.29% |
| Total Equity | €3.33 Billion | 100.00% |
BeiGene Ltd. Competitors by Market Cap
The table below lists competitors of BeiGene Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Givaudan SA
SW:GIVN
|
$25.74 Billion |
|
Viking Holdings Ltd
NYSE:VIK
|
$25.74 Billion |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
$25.75 Billion |
|
Cheniere Energy Partners LP
NYSE MKT:CQP
|
$25.77 Billion |
|
Hyundai Mobis Co.,Ltd
KO:012330
|
$25.72 Billion |
|
Mettler-Toledo International Inc
NYSE:MTD
|
$25.66 Billion |
|
Zhejiang Sanhua Co Ltd
SHE:002050
|
$25.62 Billion |
|
Shanxi Xinghuacun Fen Wine Factory Co Ltd
SHG:600809
|
$25.59 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BeiGene Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,537,327,000 to 3,332,222,000, a change of -205,105,000 (-5.8%).
- Net loss of 644,786,000 reduced equity.
- Other factors increased equity by 439,681,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-644.79 Million | -19.35% |
| Other Changes | €439.68 Million | +13.19% |
| Total Change | €- | -5.80% |
Book Value vs Market Value Analysis
This analysis compares BeiGene Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.32x to 7.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €1.13 | €17.34 | x |
| 2018-12-31 | €2.25 | €17.34 | x |
| 2019-12-31 | €1.20 | €17.34 | x |
| 2020-12-31 | €3.25 | €17.34 | x |
| 2021-12-31 | €4.69 | €17.34 | x |
| 2022-12-31 | €3.23 | €17.34 | x |
| 2023-12-31 | €2.60 | €17.34 | x |
| 2024-12-31 | €2.41 | €17.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BeiGene Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.92%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.78x
- Recent ROE (-19.35%) is above the historical average (-37.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -33.78% | -11141.78% | 0.00x | 1.15x | €-154.51 Million |
| 2017 | -13.90% | -39.06% | 0.23x | 1.56x | €-160.09 Million |
| 2018 | -38.74% | -339.91% | 0.09x | 1.29x | €-847.69 Million |
| 2019 | -98.59% | -221.53% | 0.27x | 1.68x | €-1.04 Billion |
| 2020 | -41.27% | -517.01% | 0.06x | 1.45x | €-1.98 Billion |
| 2021 | -22.64% | -120.15% | 0.14x | 1.38x | €-2.04 Billion |
| 2022 | -45.71% | -141.52% | 0.22x | 1.46x | €-2.44 Billion |
| 2023 | -24.93% | -35.86% | 0.42x | 1.64x | €-1.24 Billion |
| 2024 | -19.35% | -16.92% | 0.64x | 1.78x | €-978.01 Million |
Industry Comparison
This section compares BeiGene Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,057,695,497
- Average return on equity (ROE) among peers: -39.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BeiGene Ltd. (49B) | €3.50 Billion | -33.78% | 0.67x | $25.73 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more